Symphony (Agendia)
Symphony is a suite of
Agendia
. The results aid physicians in deciding appropriate treatment for each patient.
There are four breast cancer tests within the Symphony suite:
- MammaPrint, which assists physicians and patients in complex chemotherapy decisions by giving a clear and unambiguous high or low result of the risk of metastasis during the period when chemotherapy is effective (the first five years after diagnosis);
- TargetPrint, which identifies the presence of certain receptors and helps identify patient candidates for hormonal treatment and targeted therapies;[1]
- BluePrint, which identifies three different biological subgroups that react to specific therapies in different ways;[2]
References
- ^ Roepman P, Horlings HM, (2009) “Microarray-Based Determination of Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Status in Breast Cancer” Clin Cancer Res. 15(22):7003–11
- ^ Introducing BluePrint™: A Molecular Subtyping Profile for Breast Cancer
External links
- Agendia [1]